{"title":"Integrated transcriptomic and proteomic profiling suggests PDK4 and cell cycle-related responses to electroacupuncture in a rat model of chronic atrophic gastritis.","authors":"Ling Chen, Ting Qin, Yichen Wang, Ji Wang, Yikun Wu, Xinjing Yang, Yufeng Xie","doi":"10.3389/fgstr.2026.1894243","DOIUrl":"https://doi.org/10.3389/fgstr.2026.1894243","url":null,"abstract":"<p><strong>Background: </strong>Chronic atrophic gastritis (CAG) is a precancerous gastric lesion. Although electroacupuncture (EA) can improve CAG-related symptoms and mucosal injury, its molecular responses remain unclear.</p><p><strong>Methods: </strong>Male SPF SD rats were assigned to Control, CAG Model, and EA groups. CAG was induced by a multifactorial protocol. EA was applied at Zusanli (ST36) and Zhongwan (CV12) for 20min/day for 2 weeks. Gastric histopathology was evaluated via hematoxylin-eosin staining. To identify candidate targets of EA for CAG, integrated transcriptomics and data-independent acquisition (DIA) proteomics were employed. Subsequent validation was performed by RT-qPCR.</p><p><strong>Results: </strong>EA significantly attenuated gastric mucosal atrophy and inflammatory cell infiltration, accompanied by reduced CDK4 and CDK6 mRNA levels (<i>P</i> < 0.05). Transcriptomics identified 1662 DEGs enriched in estrogen signaling pathway and transcriptional misregulation in cancer signaling pathway. DIA-based proteomic identified 298 DEPs enriched in drug metabolism, amino acid metabolism, muscle contraction, muscle regulation, and mitochondrial metabolism. Integrated analysis identified 24 concordant DEGs/DEPs and RT-qPCR confirmed significant downregulation of PDK4 in the EA group (P<0.01).</p><p><strong>Conclusion: </strong>EA ameliorated gastric mucosa injury in CAG rats. Downregulation of PDK4 and CDK4/CDK6 mRNA was associated with EA intervention and may contribute to the amelioration of gastric mucosal injury in CAG.</p>","PeriodicalId":73085,"journal":{"name":"Frontiers in gastroenterology (Lausanne, Switzerland)","volume":"5 ","pages":"1894243"},"PeriodicalIF":0.0,"publicationDate":"2026-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13759280/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149413604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Irene Palenca, Giuseppe Esposito, Marcella Pesce, Giovanni Sarnelli
{"title":"Engineering probiotics for mucosal vaccination: from the <i>Escherichia coli</i> Nissle 1917 paradigm to a translational vaccine platform.","authors":"Irene Palenca, Giuseppe Esposito, Marcella Pesce, Giovanni Sarnelli","doi":"10.3389/fgstr.2026.1980209","DOIUrl":"https://doi.org/10.3389/fgstr.2026.1980209","url":null,"abstract":"<p><p>Mucosal vaccination is attracting renewed interest because many clinically relevant pathogens first encounter the host at gastrointestinal or respiratory surfaces, whereas most established vaccines are administered parenterally and are optimized primarily to induce systemic immunity. Engineered probiotics are emerging as living antigen-delivery vectors that may combine mucosal delivery, transient biological persistence, microbial immune signals, and programmable antigen presentation within a single platform. This strategy is particularly relevant to gastrointestinal vaccination, where access to gut-associated lymphoid tissue (GALT) may support local secretory IgA together with systemic responses. SARS-CoV-2 provides an informative experimental bridge because, despite its dominant respiratory manifestations, it can involve intestinal epithelial cells and gastrointestinal mucosal immunity. Using the pAIDA-Escherichia coli Nissle 1917 (EcN) system as a bounded proof of concept, this Perspective defines an integrated translational framework linking GALT-directed immune priming, effective mucosal antigen dose, genetic stability, chassis de-risking, biocontainment, manufacturing, potency, and post-administration clearance. We explicitly distinguish antigen delivery and immunogenicity from functional immunity, protection, and clinical efficacy, and identify the experiments required to advance probiotic-vectored mucosal vaccines toward clinically testable products.</p>","PeriodicalId":73085,"journal":{"name":"Frontiers in gastroenterology (Lausanne, Switzerland)","volume":"5 ","pages":"1980209"},"PeriodicalIF":0.0,"publicationDate":"2026-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13754662/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149413691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alessia Dalila Guarino, Giulio Calabrese, Maurizio Marra, Ersilia Nigro, Aurora Daniele, Antonio Rispo, Anna Testa, Olga Maria Nardone, Ludovica De Vito, Camilla Leo, Fabrizio Pasanisi, Fabiana Castiglione
{"title":"The hidden burden of sarcopenia in inflammatory bowel disease: a strong predictor of complications.","authors":"Alessia Dalila Guarino, Giulio Calabrese, Maurizio Marra, Ersilia Nigro, Aurora Daniele, Antonio Rispo, Anna Testa, Olga Maria Nardone, Ludovica De Vito, Camilla Leo, Fabrizio Pasanisi, Fabiana Castiglione","doi":"10.3389/fgstr.2026.1960689","DOIUrl":"10.3389/fgstr.2026.1960689","url":null,"abstract":"<p><strong>Background: </strong>Sarcopenia is an emerging predictor of adverse outcomes in inflammatory bowel disease (IBD). We assessed its prevalence and prognostic impact in a prospective cohort.</p><p><strong>Methods: </strong>Consecutive adults with IBD were prospectively enrolled (December 2023-August 2024). Sarcopenia was assessed using handgrip strength and bioelectrical impedance analysis (BIA) and patients were classified as non sarcopenic, with probable sarcopenia, or confirmed sarcopenia. Clinical worsening, IBD-related hospitalization, surgery, and infectious complications were prospectively assessed over 12 months.</p><p><strong>Results: </strong>We enrolled 113 IBD patients: 32 (28.3%) were non-sarcopenic, 73 (64.6%) had probable sarcopenia, and 8 (7.1%) had confirmed sarcopenia. Confirmed sarcopenia was associated with lower BMI, higher CRP levels, and a higher prevalence of high nutritional risk. During follow-up, clinical worsening occurred in 46.9%, 45.2%, and 87.5% of patients, respectively (p=0.074), while IBD-related hospitalization occurred in 6.2%, 11.0%, and 62.5% (p<0.001). After adjustment for baseline clinical activity, confirmed sarcopenia remained independently associated with IBD-related hospitalization (adjusted OR [aOR] 18.30, 95% CI 3.21-141.14; p<0.001). Confirmed sarcopenia was also independently associated with infectious complications after adjustment for advanced-therapy exposure (aOR 7.40, 95% CI 1.17-54.63; p=0.034). No independent association was observed between sarcopenia and clinical worsening after adjustment for age, baseline clinical activity, BMI, and CRP.</p><p><strong>Conclusions: </strong>In this prospective cohort of patients with IBD, confirmed sarcopenia was independently associated with an increased risk of IBD-related hospitalization and infectious complications over 12 months. These findings suggest that assessment of muscle strength and mass may provide clinically relevant prognostic information beyond conventional measures of disease activity and nutritional status.</p>","PeriodicalId":73085,"journal":{"name":"Frontiers in gastroenterology (Lausanne, Switzerland)","volume":"5 ","pages":"1960689"},"PeriodicalIF":0.0,"publicationDate":"2026-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13751511/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149396358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Diet meets biologics: accelerating remission in pediatric Crohn's disease - a real-world experience.","authors":"Jhoanna Valery Adauto Luizaga, María Soledad Arcucci, Katia Anabel Kulay, Flavia Vollweiler, Julieta Gallo, Vanina Pagotto, Verónica Busoni, Marina Orsi","doi":"10.3389/fgstr.2026.1951489","DOIUrl":"10.3389/fgstr.2026.1951489","url":null,"abstract":"<p><strong>Background: </strong>Exclusive enteral nutrition (EEN) and the Crohn's disease exclusion diet (CDED) plus partial enteral nutrition (PEN) induce remission in pediatric Crohn's disease (CD), but data on their use as adjuncts to biologic therapy remain limited. We aimed to determine whether CDED+PEN combined with first-line biologic therapy reduces the time to clinical and endoscopic remission, framed by STRIDE-II targets, compared with biologics alone.</p><p><strong>Methods: </strong>Single-center, retrospective cohort study of pediatric patients with CD diagnosed per the revised Porto criteria who initiated first-line anti-tumor necrosis factor-α (anti-TNF-α) therapy between January 2020 and December 2024. Patients with significant comorbidities, inconsistent follow-up, or a change in biologic target were excluded. Group 1 (G1) received CDED+PEN (Modulen-IBD<sup>®</sup>) alongside biologics with multidisciplinary support; Group 2 (G2) received biologics alone. Outcomes were time to clinical response and to clinical remission, both defined by the weighted Pediatric Crohn's Disease Activity Index (wPCDAI); time to normalization of erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), time to fecal calprotectin (FC) normalization, and time to mucosal healing (MH). Absolute changes from baseline (Δ) in wPCDAI, FC, Simple Endoscopic Score for CD (SES-CD), ESR, CRP, albumin and body mass index (BMI) were compared between groups, and effect modification by disease location was assessed using median regression models including a diet-by-location interaction term. Between-group comparisons used the Mann-Whitney U test; time-to-event outcomes were analyzed using Kaplan-Meier methods with log-rank comparison.</p><p><strong>Results: </strong>Forty patients were included (65% male; median age 12.02 years, interquartile range [IQR] 9.52-14.09): 27 in G1 and 13 in G2. Times to clinical response, clinical remission, and ESR/CRP normalization were consistently shorter in G1 without reaching statistical significance. FC normalization was achieved in 72.5% of patients overall and MH in 55.0%. Kaplan-Meier analysis showed no significant difference between groups in the cumulative incidence of either outcome (log-rank p = 0.82 for FC normalization and p = 0.54 for MH). At the prespecified time points, cumulative incidence of FC normalization at 4 months was 23.7% (G1) vs 30.8% (G2), and of MH at 12 months 16.0% (G1) vs 18.2% (G2). Among the absolute changes from baseline, wPCDAI was the only variable showing a significantly greater reduction in G1 (p = 0.029); Δ FC, SES-CD, ESR, CRP, albumin and BMI did not differ between groups. Disease location did not modify the effect of CDED+PEN on any outcome (all p for interaction > 0.10), although the small number of patients with isolated colonic disease (n = 10) renders this analysis exploratory.</p><p><strong>Conclusions: </strong>In this real-world pediatric cohort, adding CDED+PEN to first-line bi","PeriodicalId":73085,"journal":{"name":"Frontiers in gastroenterology (Lausanne, Switzerland)","volume":"5 ","pages":"1951489"},"PeriodicalIF":0.0,"publicationDate":"2026-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13751336/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149396356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Efficacy and safety of a fixed-dose papain and alpha-amylase combination in patients with functional dyspepsia: a real-world study.","authors":"S Krishna Deepak, Ankur Jain, Sangitanjan Dutta, Abhinav Jain, Soham Kshirsagar, Rashi Joshi, Archana Toppo","doi":"10.3389/fgstr.2026.1954358","DOIUrl":"10.3389/fgstr.2026.1954358","url":null,"abstract":"<p><strong>Background: </strong>Functional dyspepsia (FD) is highly prevalent and often inadequately managed because conventional therapies may have limited efficacy or tolerability. Enzyme-based therapies offer a physiologically relevant alternative by supporting digestion. This study evaluated the real-world effectiveness and safety of a fixed-dose combination (FDC) of papain and alpha-amylase in patients with FD.</p><p><strong>Methodology: </strong>This prospective, multicenter, single-arm intervention study enrolled adults with FD (Rome IV criteria) across four Indian centers. Patients received the FDC for 12 days. The primary endpoint was a ≥50% reduction in composite symptom score. Secondary endpoints included symptom resolution, time to relief, safety, and subgroup outcomes. Assessments were conducted at baseline, Day 7, and Day 12.</p><p><strong>Results: </strong>Of 160 enrolled patients, 144 (90%) completed the study. Mean symptom scores declined significantly from 9.35 ± 1.42 (baseline) to 0.15 ± 0.35 (Day 12; <i>p</i>< 0.0001), indicating 98.4% improvement. Clinical response was achieved in all patients by Day 7 and sustained on Day 12, with 85.4% achieving excellent response. The arithmetic mean (unweighted) of domain-specific resolution percentages reached 98.7% by Day 12. Median time to initial relief was approximately 4 hours. Adverse events were mild and reported in 12.5% of patients.</p><p><strong>Conclusion: </strong>The FDC demonstrated short-term rapid, substantial, and consistent symptom relief with favorable tolerability in patients with FD.</p>","PeriodicalId":73085,"journal":{"name":"Frontiers in gastroenterology (Lausanne, Switzerland)","volume":"5 ","pages":"1954358"},"PeriodicalIF":0.0,"publicationDate":"2026-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13751347/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149396357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Total glucosides of paeony in cirrhosis: mechanisms of action via the gut-liver axis - a review.","authors":"Shulan Chen, Qiang Zheng","doi":"10.3389/fgstr.2026.1981682","DOIUrl":"10.3389/fgstr.2026.1981682","url":null,"abstract":"<p><strong>Background & aim: </strong>Liver cirrhosis, the end-stage of chronic liver diseases, imposes a high global burden. Gut-liver axis dysregulation-microbiota imbalance, barrier failure, endotoxin translocation, bile acid disturbance, suppressed FXR signaling, and NLRP3 activation-drives cirrhosis progression. Total glucosides of paeony (TGP), a Paeonia lactiflora extract rich in paeoniflorin (>90%), possesses anti-inflammatory and immunomodulatory properties. However, a systematic review of TGP's mechanisms via the gut-liver axis is lacking. This review aims to systematically summarize and critically evaluate the molecular mechanisms by which TGP modulates the gut-liver axis to treat cirrhosis, covering its effects on microbiota restoration, barrier repair, bile acid normalization, FXR reactivation, and dual inhibition of NF-κB and NLRP3 inflammatory pathways, thereby providing a comprehensive mechanistic framework for its therapeutic application.</p><p><strong>Main findings: </strong>Preclinical evidence shows TGP is associated with improved microbiota balance (increased Lactobacillus, Akkermansia, Lachnospira), Through short-chain fatty acids, the expression of tight junction proteins (ZO-1, Occludin, Claudin-3) may be upregulated, and the levels of endotoxin and bacterial translocation in the portal vein may be reduced. TGP normalizes primary-to-secondary bile acid conversion (CA/CDCA to DCA/LCA), thereby activating intestinal and hepatic farnesoid X receptor (FXR). Its main component, paeoniflorin, enhances FXR through PKCα/MAPK inhibition and SIRT1 upregulation. Activated FXR dually suppresses NF-κB (directly and via Nrf2/HO-1) and inhibits NLRP3 Ser295 phosphorylation, while reducing bile acid synthesis, achieving coordinated anti-inflammatory and barrier-protective effects.</p><p><strong>Conclusion: </strong>TGP may intervene in the vicious cycle of liver cirrhosis through a hierarchical cascading reaction - barrier repair, bile acid restoration, FXR activation, and dual NF-κB/NLRP3 inhibition. Despite predominantly preclinical data, TGP's multi-target profile offers promising therapeutic potential; future large-scale clinical trials and formulation refinement are needed to enable TGP to meet the demand for the transition from preclinical evidence to clinical application, benefiting patients with liver cirrhosis.</p>","PeriodicalId":73085,"journal":{"name":"Frontiers in gastroenterology (Lausanne, Switzerland)","volume":"5 ","pages":"1981682"},"PeriodicalIF":0.0,"publicationDate":"2026-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13749035/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149388756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Afaf Awad Y Ahmad, Michael Craughwell, Lindsey Clarke, Niamh Nolan, Audrey Dillon, Zita Galvin
{"title":"Hepatic small vessel neoplasm, a first case report in a liver transplant recipient.","authors":"Afaf Awad Y Ahmad, Michael Craughwell, Lindsey Clarke, Niamh Nolan, Audrey Dillon, Zita Galvin","doi":"10.3389/fgstr.2026.1956520","DOIUrl":"10.3389/fgstr.2026.1956520","url":null,"abstract":"<p><p>Hepatic small vessel neoplasm (HSVN) is a recently recognized vascular tumor of the liver that behaves in a largely indolent fashion but carries uncertain malignant potential. Unlike hepatic angiosarcoma, HSVN lacks marked cytologic atypia and does not demonstrate diffuse p53, GLUT1, or c-Myc overexpression. We describe what appears to be the first reported case of HSVN arising in a liver allograft, highlighting diagnostic challenges and management considerations in a transplant recipient.</p>","PeriodicalId":73085,"journal":{"name":"Frontiers in gastroenterology (Lausanne, Switzerland)","volume":"5 ","pages":"1956520"},"PeriodicalIF":0.0,"publicationDate":"2026-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13745363/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149382117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jared Fehlman, Westley Peng, Christian Pfenning, Hayley McCorkle, Judy W Nee, William D Chey, Ceciel Rooker, Sarah Ballou, Allen A Lee, Prashant Singh
{"title":"Irritable bowel syndrome in the community: a cross-sectional study looking at patient experiences and challenges with the low FODMAP diet.","authors":"Jared Fehlman, Westley Peng, Christian Pfenning, Hayley McCorkle, Judy W Nee, William D Chey, Ceciel Rooker, Sarah Ballou, Allen A Lee, Prashant Singh","doi":"10.3389/fgstr.2026.1930300","DOIUrl":"https://doi.org/10.3389/fgstr.2026.1930300","url":null,"abstract":"<p><p>While a diet low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP) is the most evidence-based dietary therapy for irritable bowel syndrome (IBS), data on patient experiences with the low FODMAP diet (LFD) remains sparse. Even less information exists examining patients' experiences with the re-introduction and personalization phases of LFD, especially in the community setting. This cross-sectional study surveyed 387 participants from the mailing list of the International Foundation for Functional Gastrointestinal Disorders (IFFGD) about their experiences with LFD. Additionally, focus groups collected qualitative data about participants' experiences with the LFD diet. Despite 70% of participants reporting perceived improvement of symptoms with FODMAP restriction, 70% of participants reported that LFD was either somewhat or extremely difficult to follow and 59% of participants reported continuing the restriction phase beyond 8 weeks. 41% of participants found the re-introduction phase somewhat or extremely difficult and two-thirds took >1 month to complete it. Only 30% and 25% of participants worked with a dietitian for restriction and re-introduction phases, with many receiving their information online or via app. Finally, over 80% of participants reported they would be interested in a simplified version of the LFD. While the LFD led to perceived symptom improvement in most IBS patients, it is associated with limitations, including its complexity and restrictiveness. Furthermore, food-related fear and anxiety, particularly during restriction and reintroduction phases, pose significant challenges. These findings underscore the practical limitations LFD has, and participants expressed a strong interest in a simpler, more convenient alternative.</p>","PeriodicalId":73085,"journal":{"name":"Frontiers in gastroenterology (Lausanne, Switzerland)","volume":"5 ","pages":"1930300"},"PeriodicalIF":0.0,"publicationDate":"2026-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13739530/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149372336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ilaria Lodola, Piera Zaccari, Martina Abati, Matteo Tacelli, Paolo Giorgio Arcidiacono, Gabriele Capurso
{"title":"Serial bioelectrical impedance changes during nutritional follow-up in chronic pancreatitis.","authors":"Ilaria Lodola, Piera Zaccari, Martina Abati, Matteo Tacelli, Paolo Giorgio Arcidiacono, Gabriele Capurso","doi":"10.3389/fgstr.2026.1933330","DOIUrl":"10.3389/fgstr.2026.1933330","url":null,"abstract":"<p><strong>Introduction: </strong>Nutritional impairment in chronic pancreatitis (CP) may be present even when body mass index (BMI) and routine screening scores do not indicate overt malnutrition. We aimed to provide a bioelectrical impedance analysis (BIA)-based snapshot of body composition in a clinically selected CP cohort referred for nutritional assessment and to evaluate serial changes during follow-up.</p><p><strong>Methods: </strong>This monocentric retrospective analysis included prospectively collected data from the BIOPANCREAS registry (NCT06552078). Adults with probable or definitive CP (M-ANNHEIM criteria) undergoing clinically indicated nutritional assessment including BIA were included. Longitudinal changes in BIA-derived parameters were assessed using linear mixed-effects models with Benjamini-Hochberg false discovery rate (FDR) correction. Complete-case Friedman analyses were performed as sensitivity analyses.</p><p><strong>Results: </strong>Thirty-two patients were included (mean age 58.4 ± 15.8 years; 65.6% male). At baseline, mean BMI was 22.3 ± 3.8 kg/m² and 77.4% were at low nutritional risk according to the Malnutrition Universal Screening Tool (MUST). Low fat-free mass index (FFMI) and appendicular skeletal muscle mass index (ASMMI) were identified in 18.8% and 40.6%, respectively. BIA measurements were available in 32, 25, and 17 patients at visits I, II, and III. After FDR correction, phase angle (PhA), body cell mass percentage (BCM%), and extracellular water percentage (ECW%) changed significantly. Compared with visit I, PhA increased by 0.24° at visit II (95% confidence interval [CI] 0.06-0.42) and 0.28° at visit III (95% CI 0.07-0.49); BCM% increased by 1.48 (95% CI 0.40-2.56) and 1.80 percentage points (95% CI 0.54-3.05), respectively; and ECW% decreased by 1.41 (95% CI -2.42 to -0.40) and 1.66 percentage points (95% CI -2.84 to -0.49), respectively; All six contrasts remained significant after FDR correction (adjusted p=0.016). No significant visit II to III differences or longitudinal changes in conventional muscle-quantity indices were observed.</p><p><strong>Discussion: </strong>In this real-world cohort, BIA identified heterogeneous body-composition abnormalities despite relatively reassuring BMI and MUST findings. During nutritional follow-up, PhA and BCM% increased and ECW% decreased, while conventional muscle-quantity indices did not show significant changes. These hypothesis-generating findings support prospective controlled evaluation of serial BIA during nutritional care in CP.</p>","PeriodicalId":73085,"journal":{"name":"Frontiers in gastroenterology (Lausanne, Switzerland)","volume":"5 ","pages":"1933330"},"PeriodicalIF":0.0,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13727375/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149328126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The mind-body connection in women's reproductive health: how psychological stress shapes gut and ovarian function - a narrative review.","authors":"Arpitha Yachanahalli Purushotham, Borehalli Mayegowda Shilpa, Divya Sundaram","doi":"10.3389/fgstr.2026.1854862","DOIUrl":"10.3389/fgstr.2026.1854862","url":null,"abstract":"<p><p>Psychological stress plays a critical role in modulating women's reproductive health through integrated neuroendocrine, immune, and microbiome-mediated pathways. Activation of the hypothalamic-pituitary-adrenal (HPA) axis leads to elevated secretion of corticotropin-releasing hormone (CRH), adrenocorticotropic hormone (ACTH), and cortisol, which suppress hypothalamic gonadotropin-releasing hormone (GnRH) pulsatility, thereby disrupting the hypothalamic-pituitary-gonadal (HPG) axis. This results in reduced secretion of luteinising hormone (LH) and follicle-stimulating hormone (FSH), impairing folliculogenesis, ovulation, and menstrual cyclicity. Chronic stress further induces oxidative stress, mitochondrial dysfunction, and apoptosis in ovarian cells, thereby reducing oocyte competence and diminishing ovarian reserve. Additionally, stress-induced gut microbiota dysbiosis alters the composition of key microbial taxa, including <i>Lactobacillus, Bifidobacterium, and Clostridium</i>, disrupting the estrobolome and impairing oestrogen metabolism. This dysregulation increases intestinal permeability and promotes systemic inflammation, as evidenced by biomarkers including interleukin-6 (IL-6), tumour necrosis factor-alpha (TNF-α), and C-reactive protein (CRP), which adversely affect endometrial receptivity and implantation success. Emerging evidence also indicates that microbial metabolites such as short-chain fatty acids (SCFAs), tryptophan metabolites, and serotonin play a crucial role in modulating neuroendocrine signalling and reproductive outcomes. Despite growing evidence, the lack of standardised biomarkers and well-designed clinical trials limits translation into clinical practice. Future research should focus on integrative, personalised therapeutic approaches combining psychological interventions, lifestyle modifications, and microbiome-targeted therapies to improve reproductive outcomes and overall well-being.</p>","PeriodicalId":73085,"journal":{"name":"Frontiers in gastroenterology (Lausanne, Switzerland)","volume":"5 ","pages":"1854862"},"PeriodicalIF":0.0,"publicationDate":"2026-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13698839/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149278010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}